What is the P/E ratio of Sichuan Hebang Biotechnology Co 2024?
The Sichuan Hebang Biotechnology Co P/E ratio is 3.29.
Own the gold standard ✨ in financial data & analytics
Subscribe for $2 
Overview
Profile
Sichuan Hebang Biotechnology Co Company stock price, forecast, news, chart, split, dividend and analysis Sichuan Hebang Biotechnology Co ariva, Sichuan Hebang Biotechnology Co onvista, Sichuan Hebang Biotechnology Co finanzen.net, Sichuan Hebang Biotechnology Co aktienfinder, Sichuan Hebang Biotechnology Co marketscreener, Sichuan Hebang Biotechnology Co marketwatch, Sichuan Hebang Biotechnology Co bloomberg, Sichuan Hebang Biotechnology Co handelsblatt, Sichuan Hebang Biotechnology Co wiwo, Sichuan Hebang Biotechnology Co forum
603077.SS
CNE100001JM9
Price
Price
2.08
Today +/-
+0.00
Today %
+0.97 %
Ticker603077.SS
ISINCNE100001JM9
P
Sichuan Hebang Biotechnology Co stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Sichuan Hebang Biotechnology Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Sichuan Hebang Biotechnology Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Sichuan Hebang Biotechnology Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Sichuan Hebang Biotechnology Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Sichuan Hebang Biotechnology Co Stock Price History
| Date | Sichuan Hebang Biotechnology Co Price |
|---|---|
| 10/31/2024 | 2.08 undefined |
| 10/30/2024 | 2.06 undefined |
| 10/29/2024 | 2.06 undefined |
| 10/28/2024 | 2.11 undefined |
| 10/25/2024 | 2.09 undefined |
| 10/24/2024 | 1.99 undefined |
| 10/23/2024 | 2.02 undefined |
| 10/22/2024 | 1.95 undefined |
| 10/21/2024 | 1.94 undefined |
| 10/18/2024 | 1.97 undefined |
| 10/17/2024 | 1.92 undefined |
| 10/16/2024 | 1.98 undefined |
| 10/15/2024 | 1.96 undefined |
| 10/14/2024 | 2.02 undefined |
| 10/11/2024 | 2.00 undefined |
| 10/10/2024 | 2.07 undefined |
| 10/9/2024 | 2.05 undefined |
| 10/8/2024 | 2.21 undefined |
Sichuan Hebang Biotechnology Co Revenue, EBIT, Net Income CNE100001JM9 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Sichuan Hebang Biotechnology Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sichuan Hebang Biotechnology Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sichuan Hebang Biotechnology Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Sichuan Hebang Biotechnology Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Sichuan Hebang Biotechnology Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Sichuan Hebang Biotechnology Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sichuan Hebang Biotechnology Co’s growth potential.
Sichuan Hebang Biotechnology Co Revenue, EBIT and net profit per share
| Date | Sichuan Hebang Biotechnology Co Revenue | Sichuan Hebang Biotechnology Co EBIT | Sichuan Hebang Biotechnology Co Net Income |
|---|---|---|---|
| 2024e | 31.39 B undefined | 0 undefined | 5.51 B undefined |
| 2023 | 8.82 B undefined | 1.43 B undefined | 1.28 B undefined |
| 2022 | 13.04 B undefined | 4.51 B undefined | 3.81 B undefined |
| 2021 | 9.99 B undefined | 3.65 B undefined | 3.02 B undefined |
| 2020 | 5.26 B undefined | 520.6 M undefined | 40.9 M undefined |
| 2019 | 5.97 B undefined | 644.1 M undefined | 516.9 M undefined |
| 2018 | 6.01 B undefined | 606.5 M undefined | 363.1 M undefined |
| 2017 | 4.74 B undefined | 608.8 M undefined | 517.5 M undefined |
| 2016 | 3.46 B undefined | 392.7 M undefined | 317.8 M undefined |
| 2015 | 2.86 B undefined | 292.7 M undefined | 239.9 M undefined |
| 2014 | 2.19 B undefined | 147.9 M undefined | 671.8 M undefined |
| 2013 | 1.6 B undefined | 109.5 M undefined | 64.4 M undefined |
| 2012 | 1.74 B undefined | 464.1 M undefined | 334.9 M undefined |
| 2011 | 1.9 B undefined | 598.6 M undefined | 416.2 M undefined |
| 2010 | 1.43 B undefined | 251 M undefined | 172.8 M undefined |
| 2009 | 844.4 M undefined | 64.8 M undefined | 44.2 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2009 | 844.4 M CNY | 64.8 M CNY | 44.2 M CNY |
| 2010 | 1.43 B CNY | 251 M CNY | 172.8 M CNY |
| 2011 | 1.9 B CNY | 598.6 M CNY | 416.2 M CNY |
| 2012 | 1.74 B CNY | 464.1 M CNY | 334.9 M CNY |
| 2013 | 1.6 B CNY | 109.5 M CNY | 64.4 M CNY |
| 2014 | 2.19 B CNY | 147.9 M CNY | 671.8 M CNY |
| 2015 | 2.86 B CNY | 292.7 M CNY | 239.9 M CNY |
| 2016 | 3.46 B CNY | 392.7 M CNY | 317.8 M CNY |
| 2017 | 4.74 B CNY | 608.8 M CNY | 517.5 M CNY |
| 2018 | 6.01 B CNY | 606.5 M CNY | 363.1 M CNY |
| 2019 | 5.97 B CNY | 644.1 M CNY | 516.9 M CNY |
| 2020 | 5.26 B CNY | 520.6 M CNY | 40.9 M CNY |
| 2021 | 9.99 B CNY | 3.65 B CNY | 3.02 B CNY |
| 2022 | 13.04 B CNY | 4.51 B CNY | 3.81 B CNY |
| 2023 | 8.82 B CNY | 1.43 B CNY | 1.28 B CNY |
| 2024e | 31.39 B CNY | 0 CNY | 5.51 B CNY |
Sichuan Hebang Biotechnology Co Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.84 | 1.43 | 1.9 | 1.74 | 1.6 | 2.19 | 2.86 | 3.46 | 4.74 | 6.01 | 5.97 | 5.26 | 9.99 | 13.04 | 8.82 | 31.39 |
| - | 69.67 | 32.68 | -8.58 | -7.77 | 36.39 | 30.98 | 20.96 | 36.83 | 26.85 | -0.67 | -11.88 | 89.87 | 30.55 | -32.32 | 255.68 |
| 23.46 | 31.98 | 40.89 | 37.54 | 19.16 | 17.48 | 21.24 | 24.64 | 25.44 | 22.02 | 22.53 | 18.57 | 41.30 | 42.68 | 22.69 | - |
| 0.2 | 0.46 | 0.78 | 0.65 | 0.31 | 0.38 | 0.61 | 0.85 | 1.21 | 1.32 | 1.35 | 0.98 | 4.13 | 5.57 | 2 | 0 |
| 0.06 | 0.25 | 0.6 | 0.46 | 0.11 | 0.15 | 0.29 | 0.39 | 0.61 | 0.61 | 0.64 | 0.52 | 3.65 | 4.51 | 1.43 | 0 |
| 7.58 | 17.53 | 31.47 | 26.71 | 6.80 | 6.73 | 10.20 | 11.32 | 12.84 | 10.08 | 10.79 | 9.89 | 36.53 | 34.60 | 16.22 | - |
| 0.04 | 0.17 | 0.42 | 0.33 | 0.06 | 0.67 | 0.24 | 0.32 | 0.52 | 0.36 | 0.52 | 0.04 | 3.02 | 3.81 | 1.28 | 5.51 |
| - | 290.91 | 141.86 | -19.71 | -80.84 | 948.44 | -64.38 | 32.64 | 63.09 | -29.79 | 42.15 | -92.25 | 7,445.00 | 26.11 | -66.29 | 329.54 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 5.94 | 5.94 | 4.62 | 5.14 | 5.94 | 6.67 | 7.29 | 7.77 | 8.83 | 8.83 | 8.83 | 8.83 | 8.44 | 8.7 | 8.71 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Sichuan Hebang Biotechnology Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Sichuan Hebang Biotechnology Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Sichuan Hebang Biotechnology Co stock margins CNE100001JM9 ·
The Sichuan Hebang Biotechnology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sichuan Hebang Biotechnology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sichuan Hebang Biotechnology Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Sichuan Hebang Biotechnology Co's sales revenue. A higher gross margin percentage indicates that the Sichuan Hebang Biotechnology Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Sichuan Hebang Biotechnology Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Sichuan Hebang Biotechnology Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sichuan Hebang Biotechnology Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sichuan Hebang Biotechnology Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sichuan Hebang Biotechnology Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Sichuan Hebang Biotechnology Co Margin History
| Sichuan Hebang Biotechnology Co Gross margin | Sichuan Hebang Biotechnology Co Profit margin | Sichuan Hebang Biotechnology Co EBIT margin | Sichuan Hebang Biotechnology Co Profit margin |
|---|---|---|---|
| 2024e | 22.7 % | 0 % | 17.56 % |
| 2023 | 22.7 % | 16.22 % | 14.54 % |
| 2022 | 42.68 % | 34.6 % | 29.2 % |
| 2021 | 41.31 % | 36.53 % | 30.22 % |
| 2020 | 18.58 % | 9.9 % | 0.78 % |
| 2019 | 22.54 % | 10.79 % | 8.66 % |
| 2018 | 22.03 % | 10.09 % | 6.04 % |
| 2017 | 25.45 % | 12.85 % | 10.92 % |
| 2016 | 24.66 % | 11.34 % | 9.18 % |
| 2015 | 21.24 % | 10.22 % | 8.38 % |
| 2014 | 17.51 % | 6.77 % | 30.74 % |
| 2013 | 19.16 % | 6.83 % | 4.02 % |
| 2012 | 37.55 % | 26.71 % | 19.27 % |
| 2011 | 40.94 % | 31.51 % | 21.91 % |
| 2010 | 32.02 % | 17.52 % | 12.06 % |
| 2009 | 23.54 % | 7.67 % | 5.23 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2009 | 23.54 % | 7.67 % | 5.23 % |
| 2010 | 32.02 % | 17.52 % | 12.06 % |
| 2011 | 40.94 % | 31.51 % | 21.91 % |
| 2012 | 37.55 % | 26.71 % | 19.27 % |
| 2013 | 19.16 % | 6.83 % | 4.02 % |
| 2014 | 17.51 % | 6.77 % | 30.74 % |
| 2015 | 21.24 % | 10.22 % | 8.38 % |
| 2016 | 24.66 % | 11.34 % | 9.18 % |
| 2017 | 25.45 % | 12.85 % | 10.92 % |
| 2018 | 22.03 % | 10.09 % | 6.04 % |
| 2019 | 22.54 % | 10.79 % | 8.66 % |
| 2020 | 18.58 % | 9.9 % | 0.78 % |
| 2021 | 41.31 % | 36.53 % | 30.22 % |
| 2022 | 42.68 % | 34.6 % | 29.2 % |
| 2023 | 22.7 % | 16.22 % | 14.54 % |
| 2024e | 22.7 % | 0 % | 17.56 % |
Sichuan Hebang Biotechnology Co Stock Sales Revenue, EBIT, Earnings per Share CNE100001JM9 ·
The Sichuan Hebang Biotechnology Co earnings per share therefore indicates how much revenue Sichuan Hebang Biotechnology Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Sichuan Hebang Biotechnology Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Sichuan Hebang Biotechnology Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Sichuan Hebang Biotechnology Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sichuan Hebang Biotechnology Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Sichuan Hebang Biotechnology Co Revenue, EBIT and net profit per share
| Date | Sichuan Hebang Biotechnology Co Sales per Share | Sichuan Hebang Biotechnology Co EBIT per share | Sichuan Hebang Biotechnology Co Earnings per Share |
|---|---|---|---|
| 2024e | 3.91 undefined | 0 undefined | 0.69 undefined |
| 2023 | 1.01 undefined | 0.16 undefined | 0.15 undefined |
| 2022 | 1.5 undefined | 0.52 undefined | 0.44 undefined |
| 2021 | 1.18 undefined | 0.43 undefined | 0.36 undefined |
| 2020 | 0.6 undefined | 0.06 undefined | 0 undefined |
| 2019 | 0.68 undefined | 0.07 undefined | 0.06 undefined |
| 2018 | 0.68 undefined | 0.07 undefined | 0.04 undefined |
| 2017 | 0.54 undefined | 0.07 undefined | 0.06 undefined |
| 2016 | 0.45 undefined | 0.05 undefined | 0.04 undefined |
| 2015 | 0.39 undefined | 0.04 undefined | 0.03 undefined |
| 2014 | 0.33 undefined | 0.02 undefined | 0.1 undefined |
| 2013 | 0.27 undefined | 0.02 undefined | 0.01 undefined |
| 2012 | 0.34 undefined | 0.09 undefined | 0.07 undefined |
| 2011 | 0.41 undefined | 0.13 undefined | 0.09 undefined |
| 2010 | 0.24 undefined | 0.04 undefined | 0.03 undefined |
| 2009 | 0.14 undefined | 0.01 undefined | 0.01 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2009 | 0.14 CNY | 0.01 CNY | 0.01 CNY |
| 2010 | 0.24 CNY | 0.04 CNY | 0.03 CNY |
| 2011 | 0.41 CNY | 0.13 CNY | 0.09 CNY |
| 2012 | 0.34 CNY | 0.09 CNY | 0.07 CNY |
| 2013 | 0.27 CNY | 0.02 CNY | 0.01 CNY |
| 2014 | 0.33 CNY | 0.02 CNY | 0.1 CNY |
| 2015 | 0.39 CNY | 0.04 CNY | 0.03 CNY |
| 2016 | 0.45 CNY | 0.05 CNY | 0.04 CNY |
| 2017 | 0.54 CNY | 0.07 CNY | 0.06 CNY |
| 2018 | 0.68 CNY | 0.07 CNY | 0.04 CNY |
| 2019 | 0.68 CNY | 0.07 CNY | 0.06 CNY |
| 2020 | 0.6 CNY | 0.06 CNY | 0 CNY |
| 2021 | 1.18 CNY | 0.43 CNY | 0.36 CNY |
| 2022 | 1.5 CNY | 0.52 CNY | 0.44 CNY |
| 2023 | 1.01 CNY | 0.16 CNY | 0.15 CNY |
| 2024e | 3.91 CNY | 0 CNY | 0.69 CNY |
Sichuan Hebang Biotechnology Co business model
Sichuan Hebang Biotechnology Co is one of the most popular companies on Eulerpool.com.
Sichuan Hebang Biotechnology Co Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Sichuan Hebang Biotechnology Co historical P/E ratio, EBIT multiple, and P/S ratio
Sichuan Hebang Biotechnology Co shares outstanding CNE100001JM9 ·
The number of shares was Sichuan Hebang Biotechnology Co in 2023 — This indicates how many shares 8.706 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Sichuan Hebang Biotechnology Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Sichuan Hebang Biotechnology Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Sichuan Hebang Biotechnology Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sichuan Hebang Biotechnology Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2009 | 5.94 B Aktien |
| 2010 | 5.94 B Aktien |
| 2011 | 4.62 B Aktien |
| 2012 | 5.14 B Aktien |
| 2013 | 5.94 B Aktien |
| 2014 | 6.67 B Aktien |
| 2015 | 7.29 B Aktien |
| 2016 | 7.77 B Aktien |
| 2017 | 8.83 B Aktien |
| 2018 | 8.83 B Aktien |
| 2019 | 8.83 B Aktien |
| 2020 | 8.83 B Aktien |
| 2021 | 8.44 B Aktien |
| 2022 | 8.7 B Aktien |
| 2023 | 8.71 B Aktien |
| 2024e | 8.71 B Aktien |
Sichuan Hebang Biotechnology Co stock splits
In Sichuan Hebang Biotechnology Co's history, there have been no stock splits.
Sichuan Hebang Biotechnology Co dividend history and estimates CNE100001JM9 ·
In 2023, Sichuan Hebang Biotechnology Co paid a dividend amounting to 0.05 CNY. Dividend means that Sichuan Hebang Biotechnology Co distributes a portion of its profits to its owners.
3 years
5 years
10 years
25 Years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for Sichuan Hebang Biotechnology Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Sichuan Hebang Biotechnology Co’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating Sichuan Hebang Biotechnology Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Sichuan Hebang Biotechnology Co Dividend History
| Date | Sichuan Hebang Biotechnology Co Dividend |
|---|---|
| 2024e | 0.05 undefined |
| 2023 | 0.05 undefined |
| 2022 | 0.02 undefined |
| 2018 | 0.02 undefined |
| 2017 | 0 undefined |
| 2016 | 0 undefined |
| 2015 | 0.02 undefined |
| 2014 | 0.01 undefined |
| 2013 | 0.07 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2009 | 0 CNY | 0 CNY |
| 2010 | 0 CNY | 0 CNY |
| 2011 | 0 CNY | 0 CNY |
| 2012 | 0 CNY | 0 CNY |
| 2013 | 0.07 CNY | 0 CNY |
| 2014 | 0.01 CNY | 0 CNY |
| 2015 | 0.02 CNY | 0 CNY |
| 2016 | 0 CNY | 0 CNY |
| 2017 | 0 CNY | 0 CNY |
| 2018 | 0.02 CNY | 0 CNY |
| 2019 | 0 CNY | 0 CNY |
| 2020 | 0 CNY | 0 CNY |
| 2021 | 0 CNY | 0 CNY |
| 2022 | 0.02 CNY | 0 CNY |
| 2023 | 0.05 CNY | 0 CNY |
| 2024e | 0 CNY | 0.05 CNY |
Sichuan Hebang Biotechnology Co dividend payout ratio CNE100001JM9 ·
In 2023, Sichuan Hebang Biotechnology Co had a payout ratio of 14.71%. The payout ratio indicates the percentage of the company's profits that Sichuan Hebang Biotechnology Co distributes as dividends.
3 years
5 years
10 years
25 Years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for Sichuan Hebang Biotechnology Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for Sichuan Hebang Biotechnology Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate Sichuan Hebang Biotechnology Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Sichuan Hebang Biotechnology Co Payout Ratio History
| Date | Sichuan Hebang Biotechnology Co Payout ratio |
|---|---|
| 2024e | 11.42 % |
| 2023 | 14.71 % |
| 2022 | 3.43 % |
| 2021 | 16.12 % |
| 2020 | 24.59 % |
| 2019 | 20.33 % |
| 2018 | 50 % |
| 2017 | 7.58 % |
| 2016 | 11.36 % |
| 2015 | 77.67 % |
| 2014 | 6.7 % |
| 2013 | 667 % |
| 2012 | 20.33 % |
| 2011 | 20.33 % |
| 2010 | 20.33 % |
| 2009 | 20.33 % |
| Payout ratio | |
|---|---|
| 2009 | 20.33 % |
| 2010 | 20.33 % |
| 2011 | 20.33 % |
| 2012 | 20.33 % |
| 2013 | 667 % |
| 2014 | 6.7 % |
| 2015 | 77.67 % |
| 2016 | 11.36 % |
| 2017 | 7.58 % |
| 2018 | 50 % |
| 2019 | 20.33 % |
| 2020 | 24.59 % |
| 2021 | 16.12 % |
| 2022 | 3.43 % |
| 2023 | 14.71 % |
| 2024e | 11.42 % |
Unfortunately, there are currently no price targets and forecasts available for Sichuan Hebang Biotechnology Co.
Eulerpool ESG Scorecard© for the Sichuan Hebang Biotechnology Co stock
Eulerpool World ESG Rating (EESG©)
22/ 100
🌱 Environment
48
👫 Social
2
🏛️ Governance
17
Environment
Scope 1 - Direct Emissions | — |
Scope 2 - Indirect emissions from purchased energy | — |
Scope 3 - Indirect emissions within the value chain | — |
Total CO₂ emissions | — |
| CO₂ reduction strategy | ✅ |
| Coal energy | ❌ |
| Nuclear power | ❌ |
| Animal experiments | ❌ |
| Fur & Leather | — |
| Pesticides | ✅ |
| Palm Oil | — |
| Tobacco | ❌ |
| Genetically modified organisms | ❌ |
| Climate concept | — |
| Sustainable forestry | — |
| Recycling regulations | ❌ |
| Environmentally friendly packaging | ❌ |
| Hazardous substances | ❌ |
| Fuel consumption and efficiency | ❌ |
| Water consumption and efficiency | ❌ |
Social
| Percentage of female employees | — |
| Percentage of women in management | — |
| Percentage of Asian employees | — |
| Share of Asian management | — |
| Percentage of Hispanic/Latino employees | — |
| Hispano/Latino Management share | — |
| Percentage of Black employees | — |
| Black Management Share | — |
| Percentage of white employees | — |
| White Management Share | — |
| Adult content | ❌ |
| Alcohol | ❌ |
| Weapons | — |
| Firearms | ❌ |
| Gambling | ❌ |
| Military contracts | ❌ |
| Human rights concept | ❌ |
| Privacy concept | — |
| Occupational health and safety | ❌ |
| Catholic | ✅ |
Governance (Corporate Governance)
| Environmental reporting | ✅ |
| Stakeholder Engagement | ❌ |
| Call Back Policies | ❌ |
| Antitrust law | ❌ |
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Sichuan Hebang Biotechnology Co shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 24.46947 % | Sichuan Hebang Investment Group Co., Ltd. | 1,963,779,103 | 0 | 9/30/2023 |
| 6.53372 % | Sichuan Salt Industry Corporation | 524,359,246 | 0 | 9/30/2023 |
| 5.14156 % | He (Zheng Gang) | 412,632,000 | 0 | 9/30/2023 |
| 3.66145 % | Sichuan Hebang Biotechnology Corporation Limited - 2nd ESOP | 293,847,033 | 0 | 9/30/2023 |
| 0.84394 % | Gao (Xulei) | 67,730,096 | 0 | 9/30/2023 |
| 0.77720 % | Ren (Juan) | 62,373,906 | -98,000 | 9/30/2023 |
| 0.56321 % | China Southern Asset Management Co. Ltd. | 45,199,723 | 11,180,000 | 9/30/2023 |
| 0.48639 % | Zhao (Yong) | 39,035,034 | 0 | 9/30/2023 |
| 0.29681 % | Wang (Can) | 23,820,000 | 23,820,000 | 9/30/2023 |
| 0.23677 % | The Vanguard Group, Inc. | 19,002,203 | 0 | 3/31/2024 |
1
2
3
4
5
...
10
Sichuan Hebang Biotechnology Co Executives and Management Board
Mr. Xiaoping Zeng62
Sichuan Hebang Biotechnology Co Chairman of the Board, General Manager (since 2017)
Compensation 2 M
Mr. Zhenggang He69
Sichuan Hebang Biotechnology Co Director (since 2002)
Compensation 1.5 M
Mr. Jun Wang52
Sichuan Hebang Biotechnology Co Chief Financial Officer, Deputy General Manager, Director (since 2008)
Compensation 1.49 M
Mr. Anping Liu60
Sichuan Hebang Biotechnology Co Deputy General Manager
Compensation 480,000
Ms. Xueling Qin48
Sichuan Hebang Biotechnology Co Director
Compensation 200,000
1
2
3
Sichuan Hebang Biotechnology Co Supply Chain
| Name | Relationship | Two-week correlation | One-month correlation | Three-Month Correlation | Six-Month Correlation | One Year Correlation | Two-Year Correlation |
|---|---|---|---|---|---|---|---|
 PetroChina H | SupplierCustomer | 0,88 | -0,07 | 0,39 | 0,18 | 0,46 | 0,87 |
| SupplierCustomer | 0,78 | 0,82 | 0,90 | 0,41 | -0,29 | 0,55 | |
| SupplierCustomer | 0,67 | -0,25 | 0,51 | 0,14 | -0,69 | 0,48 | |
| SupplierCustomer | -0,55 | -0,35 | -0,17 | 0,07 | -0,24 | 0,62 |
1
Most common questions regarding Sichuan Hebang Biotechnology Co
What is the P/S ratio of Sichuan Hebang Biotechnology Co 2024?
The Sichuan Hebang Biotechnology Co P/S ratio is 0.58.
What is the Quality Investing of Sichuan Hebang Biotechnology Co?
The Quality Investing for Sichuan Hebang Biotechnology Co is 7/10.
What is the revenue of Sichuan Hebang Biotechnology Co 2024?
The expected Sichuan Hebang Biotechnology Co revenue is 31.39 B CNY.
How high is the profit of Sichuan Hebang Biotechnology Co 2024?
The expected Sichuan Hebang Biotechnology Co profit is 5.51 B CNY.
What is the business model of Sichuan Hebang Biotechnology Co
No history available for Sichuan Hebang Biotechnology Co.
What is the Sichuan Hebang Biotechnology Co dividend?
Sichuan Hebang Biotechnology Co pays a dividend of 0.02 CNY distributed over payouts per year.
How often does Sichuan Hebang Biotechnology Co pay dividends?
The dividend cannot currently be calculated for Sichuan Hebang Biotechnology Co or the company does not pay out a dividend.
What is the Sichuan Hebang Biotechnology Co ISIN?
The ISIN of Sichuan Hebang Biotechnology Co is CNE100001JM9.
What is the Sichuan Hebang Biotechnology Co ticker?
The ticker of Sichuan Hebang Biotechnology Co is 603077.SS.
How much dividend does Sichuan Hebang Biotechnology Co pay?
Over the past 12 months, Sichuan Hebang Biotechnology Co paid a dividend of 0.05 CNY . This corresponds to a dividend yield of about 2.16 %. For the coming 12 months, Sichuan Hebang Biotechnology Co is expected to pay a dividend of 0.05 CNY.
What is the dividend yield of Sichuan Hebang Biotechnology Co?
The current dividend yield of Sichuan Hebang Biotechnology Co is 2.16 %.
When does Sichuan Hebang Biotechnology Co pay dividends?
Sichuan Hebang Biotechnology Co pays a quarterly dividend. This is distributed in the months of August, July, June, July.
How secure is the dividend of Sichuan Hebang Biotechnology Co?
Sichuan Hebang Biotechnology Co paid dividends every year for the past 3 years.
What is the dividend of Sichuan Hebang Biotechnology Co?
For the upcoming 12 months, dividends amounting to 0.05 CNY are expected. This corresponds to a dividend yield of 2.16 %.
In which sector is Sichuan Hebang Biotechnology Co located?
Sichuan Hebang Biotechnology Co is assigned to the 'Commodities' sector.
Wann musste ich die Aktien von Sichuan Hebang Biotechnology Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Sichuan Hebang Biotechnology Co from 6/7/2023 amounting to 0.045 CNY, you needed to have the stock in your portfolio before the ex-date on 6/7/2023.
When did Sichuan Hebang Biotechnology Co pay the last dividend?
The last dividend was paid out on 6/7/2023.
What was the dividend of Sichuan Hebang Biotechnology Co in the year 2023?
In the year 2023, Sichuan Hebang Biotechnology Co distributed 0.015 CNY as dividends.
In which currency does Sichuan Hebang Biotechnology Co pay out the dividend?
The dividends of Sichuan Hebang Biotechnology Co are distributed in CNY.
Sichuan Hebang Biotechnology Co stock
Sector
Commodities
Industry
Commodity Chemicals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website Sichuan Hebang Biotechnology Co
Country
People's Republic of China 🇨🇳
Currency
CNY
Initial public offering
Jul 31, 2012
GOSIN
Global Open Securities Identification Number
Cusip
Y7931D103
Market capitalization
Quality Investing
7 / 10Details
PEG
0
P/E ratio
Forward P/E ratio
3.03
P/S ratio
Forward P/S ratio
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
5.32 %
Dividend
Dividend yield
2.16 %
Dividend growth Ø5Y
—
Dividend payments per year
Dividend paid since
2 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
25.83 %
Sichuan Hebang Biotechnology Co Peer Group
Sichuan Hebang Biotechnology Co Eulerpool News
Sichuan Hebang Biotechnology Co News
Sichuan Hebang Biotechnology Co Ticker
| Stock Exchange | Sichuan Hebang Biotechnology Co Ticker |
|---|---|
| SHH | 603077.SS |
Sichuan Hebang Biotechnology Co FIGI
| Sichuan Hebang Biotechnology Co Ticker | Sichuan Hebang Biotechnology Co FIGI |
|---|---|
| 603077:CH | BBG001S0V760 |
| 603077:CG | BBG002N45WL2 |
| 603077:C1 | BBG00709JGQ0 |
All fundamentals about Sichuan Hebang Biotechnology Co
Our stock analysis for Sichuan Hebang Biotechnology Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sichuan Hebang Biotechnology Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Sichuan Hebang Biotechnology Co Revenue
- Sichuan Hebang Biotechnology Co Net Income
- Sichuan Hebang Biotechnology Co P/E
- Sichuan Hebang Biotechnology Co P/S
- Sichuan Hebang Biotechnology Co EBIT
- Sichuan Hebang Biotechnology Co Dividend
- Sichuan Hebang Biotechnology Co Stocks
- Sichuan Hebang Biotechnology Co Market capitalization
- Sichuan Hebang Biotechnology Co Debt
- Sichuan Hebang Biotechnology Co Liabilities
- Sichuan Hebang Biotechnology Co Equity
- Sichuan Hebang Biotechnology Co AAQS
- Sichuan Hebang Biotechnology Co Employees
- Sichuan Hebang Biotechnology Co ROE
- Sichuan Hebang Biotechnology Co ROA
- Sichuan Hebang Biotechnology Co ROCE